Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
parkinson's neuritis neuralgia myasthenia gravis lactic acidosis ataxia seizure tinnitus migraine hypotoniaYour Article Summary
The functional index for living with multiple sclerosis: development and validation of a new quality of life questionnaire
Multiple Sclerosis, 09/11/09
Wesson JM et al. – Internal consistency reliabilities ranged from 0.80 to 0.90, demonstrating that items were grouped into the appropriate subscale domains and that the subscale domains and the questionnaire as a whole exhibited good directionality. Test–retest reproducibility was 0.91.
Related Articles
Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis
Brain, 11/25/09
Relevance Score: 69%
Increased cerebrospinal fluid chitotriosidase index in patients with multiple sclerosis
Acta Neurologica Scandinavica, 11/23/09
Relevance Score: 69%
APOE-epsilon4 is not associated with cognitive impairment in relapsing-remitting multiple sclerosis
Multiple Sclerosis, 11/19/09
Relevance Score: 69%
Cochlear implantation in a profoundly deaf patient who also suffers from multiple sclerosis - a case study
Cochlear Implants International, 10/27/09
Relevance Score: 69%
A single-centre, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis
Multiple Sclerosis, 10/01/09
Relevance Score: 69%
Today in Demyelinating Disorders...keeping you current
Receive free subspecialty "5-minute updates" via email
Micro-ribonucleic acid profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47
Brain, 12/04/09
Dysregulated Epstein-Barr virus infection in patients with CIDP
Journal of Neuroimmunology, 12/04/09
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double- blind, randomized, multicentre, placebo-controlled trial
Amyotrophic Lateral Sclerosis, 12/04/09
Sponsor
Article Search
Sponsor


See Latest Articles


